{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Moon HH"],"funding":["EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100004755)"],"pagination":["384"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12293318"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(7)"],"pubmed_abstract":["This retrospective cohort study evaluated characteristics, treatment patterns, and clinical outcomes in adults with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving first-line (1L) systemic treatment with or without avelumab 1L maintenance (1LM) between January 2020 and July 2023. The index date was the first date with a claim for 1L systemic therapy after a la/mUC diagnosis. Patients with continuous health plan enrollment for ≥6 months before and ≥1 month after the index date were identified from Carelon Research's Healthcare Integrated Research Database. Of 2820 patients receiving 1L treatment, 37.0% received platinum-based chemotherapy (PBC); 39.0%, immuno-oncology (IO) monotherapy; and 24.0%, other therapies. Renal disease and other comorbidities influenced 1L regime"],"journal":["Current oncology (Toronto, Ont.)"],"pubmed_title":["Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study."],"pmcid":["PMC12293318"],"funding_grant_id":["N/A"],"pubmed_authors":["Ike C","Dixon RW","Crowe CL","Kearney M","Tonnu-Mihara I","Barron J","Moon HH","Venkataraman M","Morris V"],"additional_accession":[]},"is_claimable":false,"name":"Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study.","description":"This retrospective cohort study evaluated characteristics, treatment patterns, and clinical outcomes in adults with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving first-line (1L) systemic treatment with or without avelumab 1L maintenance (1LM) between January 2020 and July 2023. The index date was the first date with a claim for 1L systemic therapy after a la/mUC diagnosis. Patients with continuous health plan enrollment for ≥6 months before and ≥1 month after the index date were identified from Carelon Research's Healthcare Integrated Research Database. Of 2820 patients receiving 1L treatment, 37.0% received platinum-based chemotherapy (PBC); 39.0%, immuno-oncology (IO) monotherapy; and 24.0%, other therapies. Renal disease and other comorbidities influenced 1L regime","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2025-08-28T03:09:21.322Z","creation":"2025-08-28T03:09:21.322Z"},"accession":"S-EPMC12293318","cross_references":{"pubmed":["40710195"],"doi":["10.3390/curroncol32070384"]}}